Insilico Medicine Rises Over 4% on First AI Drug Discovery Milestone with Servier, Sets New Record for PCC Output

Stock News11:10

According to Zhitong Finance APP, Insilico Medicine (HKEX: 03696) rose more than 4%, up 4.04% as of press time to HK$40.68, with a turnover of HK$278 million.

On the news front, Insilico Medicine announced this morning that it has achieved an early drug discovery milestone in its multi-year, AI-driven drug discovery collaboration with Servier, triggering a milestone payment from Servier of an undisclosed amount.

This multi-year R&D collaboration, first announced in early 2026, has a total value of up to US$888 million, including US$32 million in upfront and near-term R&D milestone payments.

Notably, thanks to the broad global recognition of its AI platform and pipeline assets, Insilico Medicine achieved total revenue of approximately US$106 million in the first half of this year, a year-on-year increase of 287%; it also achieved adjusted net profit of more than US$51 million, marking its first profitable half-year since listing.

As of now, Insilico Medicine has nominated 11 preclinical candidate compounds (PCCs) in the first 10 months of 2026, setting a new historical record for the company's annual pipeline output.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment